Metacrine, Inc.
Biotechnology ResearchCalifornia, United States2-10 Employees
Metacrine, Inc. is a clinical-stage biotechnology company focused on developing differentiated therapies for liver and gastrointestinal diseases. Its lead efforts center on targeting the farnesoid X receptor (FXR), an approach intended to provide sustained target engagement and potency to improve outcomes for conditions such as non-alcoholic steatohepatitis (NASH). The company has established a proprietary library of FXR-related compounds and has identified two oral candidates, MET409 and MET642, developed to address liver and GI diseases. Based in San Diego, California, Metacrine operates in the biotechnology research sector, with a small team driving its discovery and development programs. While its recent corporate history includes a merger-related transition involving Equillium, the core focus remains on advancing FXR-directed therapies through its platform.